Expression of ABCB1, ABCC1 and 3 and ABCG2 in glioblastoma and their relevance in relation to clinical survival surrogates

[1] Louis DN(2021)The 2021 WHO Classification of Tumors of the Central Nervous System: a summary Neurooncology 23 1231-1251

[2] Perry A(2019)CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016 Neurooncology 21 v1-v100

[3] Wesseling P(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996

[4] Ostrom QT(2011)Molecular Heterogeneity in Glioblastoma: Therapeutic Opportunities and Challenges Semin Oncol 38 243-253

[5] Cioffi G(2010)Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma J Clin Oncol 28 4722-4729

[6] Gittleman H(2011)Novel diagnostic and therapeutic approaches to malignant glioma Swiss Med Wkly 141 w13210-206

[7] Stupp R(2019)Challenges to curing primary brain tumours Nat Rev Clin Oncol 5 198-68

[8] Mason WP(2005)Optimal role of temozolomide in the treatment of malignant gliomas Curr Neurol Neurosci 20 63-1768

[9] van den Bent MJ(2001)Drug Resistance in Cancer: A Perspective Cancer Metast Rev 10 1757-290

[10] Nicholas MK(2010)Reversal of Multidrug Resistance by Natural Substances from Plants Curr Top Med Chem 3 281-16

[1] Louis DN(2021)The 2021 WHO Classification of Tumors of the Central Nervous System: a summary Neurooncology 23 1231-1251

[2] Perry A(2019)CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016 Neurooncology 21 v1-v100

[3] Wesseling P(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996

[4] Ostrom QT(2011)Molecular Heterogeneity in Glioblastoma: Therapeutic Opportunities and Challenges Semin Oncol 38 243-253

[5] Cioffi G(2010)Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma J Clin Oncol 28 4722-4729

[6] Gittleman H(2011)Novel diagnostic and therapeutic approaches to malignant glioma Swiss Med Wkly 141 w13210-206

[7] Stupp R(2019)Challenges to curing primary brain tumours Nat Rev Clin Oncol 5 198-68

[8] Mason WP(2005)Optimal role of temozolomide in the treatment of malignant gliomas Curr Neurol Neurosci 20 63-1768

[9] van den Bent MJ(2001)Drug Resistance in Cancer: A Perspective Cancer Metast Rev 10 1757-290

[10] Nicholas MK(2010)Reversal of Multidrug Resistance by Natural Substances from Plants Curr Top Med Chem 3 281-16